Biodexa Pharmaceuticals (BDRX) Net Income towards Common Stockholders (2013 - 2025)

Biodexa Pharmaceuticals has reported Net Income towards Common Stockholders for 13 years, with the latest figure at -$5.1 million in Q2 2025.

• Quarterly Net Income towards Common Stockholders changed N/A year-over-year to -$5.1 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$8.3 million (up 51.14% YoY) and the FY2025 annual result came in at -$8.7 million, down 171.06% from the prior year.
• Net Income towards Common Stockholders retreated to -$5.1 million in Q2 2025 per BDRX's latest filing, from -$3.2 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$3.2 million in Q4 2024 and troughed at -$9.3 million in Q4 2023.
• A 5-year average of -$5.1 million and a median of -$4.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2021 and 2023: Net Income towards Common Stockholders surged 80.98% in 2021, then plunged 158.92% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$7.4 million in 2021, then jumped by 51.27% to -$3.6 million in 2022, then slumped by 158.92% to -$9.3 million in 2023, then soared by 65.45% to -$3.2 million in 2024, then slumped by 58.3% to -$5.1 million in 2025.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$5.1 million, -$3.2 million, and -$9.3 million for Q2 2025, Q4 2024, and Q4 2023 respectively.